Drug Interactions Between Intramuscular Medications and Lithium
Intramuscular ziprasidone can cause lithium intoxication and should be used with extreme caution or avoided in patients on lithium therapy. 1
Critical Interaction: IM Ziprasidone + Lithium
The most clinically significant interaction documented involves intramuscular ziprasidone, which has been directly associated with lithium intoxication in schizoaffective patients. 1 The mechanism appears related to rapid increases in ziprasidone serum levels after parenteral administration, potentially affecting lithium excretion and leading to toxic lithium levels. This represents a serious safety concern requiring immediate clinical attention.
Clinical Presentation of Lithium Toxicity
When this interaction occurs, patients develop classic signs of lithium intoxication including:
- Diarrhea and vomiting
- Tremor and ataxia
- Drowsiness and confusion
- Muscular weakness 2
General IM Antipsychotic Considerations
While the ziprasidone interaction is specifically documented, caution is warranted with all antipsychotic combinations and lithium, particularly haloperidol. An encephalopathic syndrome (weakness, lethargy, fever, tremulousness, confusion, extrapyramidal symptoms, elevated enzymes) has occurred with lithium plus haloperidol, though causality remains unestablished. 2 Patients receiving combined lithium and any antipsychotic therapy require close monitoring for early neurological toxicity.
Key Drug Classes That Increase Lithium Levels
Beyond antipsychotics, several medication classes critically interact with lithium by reducing renal clearance:
NSAIDs (Highest Risk)
NSAIDs represent the most significant risk for lithium toxicity and are particularly dangerous as over-the-counter medications. 3 Indomethacin and piroxicam cause significant increases in steady-state lithium concentrations, and COX-2 inhibitors (like celecoxib) increase lithium levels by approximately 17%. 2 Monitor lithium levels closely when initiating or discontinuing any NSAID. 2
Diuretics and ACE Inhibitors
These agents cause sodium loss, which reduces renal lithium clearance and increases serum levels with risk of toxicity. 2, 4 When used concomitantly, lithium dosage typically requires reduction with more frequent plasma level monitoring. 2
AT1 Antagonists
Similar to ACE inhibitors, these affect renal function and lithium excretion. 3
Monitoring Algorithm for IM Medications + Lithium
Before administering any IM medication to a lithium patient:
- Check recent lithium level (ideally within 24-48 hours)
- Assess hydration status and sodium intake
- Review all concurrent medications, especially NSAIDs, diuretics, ACE inhibitors
If IM ziprasidone is being considered:
- Strongly consider alternative agents
- If no alternative exists, obtain baseline lithium level immediately before administration
- Recheck lithium level 24-48 hours post-administration
- Monitor closely for signs of toxicity
For other IM antipsychotics:
- Obtain baseline lithium level
- Monitor for neurological symptoms during and after administration
- Discontinue both agents immediately if encephalopathic symptoms develop
Critical Pitfalls to Avoid
- Never assume IM formulations are safer than oral regarding drug interactions—the rapid serum level increase with parenteral administration may actually increase interaction risk 1
- Don't overlook patient-purchased NSAIDs—specifically ask about over-the-counter ibuprofen, naproxen, and aspirin use 3
- Maintain adequate hydration and sodium intake (2500-3000 mL fluid daily) as dehydration from any cause potentiates lithium toxicity 2
- Remember that neuromuscular blocking agents have prolonged effects with lithium, requiring dosage adjustments during procedures 2
Special Circumstances
Environmental factors increasing lithium levels include protracted sweating, diarrhea, and febrile illness—all require temporary dose reduction or cessation with supplemental fluid and salt administration. 2 Age, renal function, and female sex independently affect lithium levels and must be factored into risk assessment. 3